We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAKR.L Regulatory News (AKR)

  • There is currently no data for AKR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

BreathScan Alcohol Detection - Product Extension

9 Jun 2010 07:00

RNS Number : 2718N
Akers Biosciences, Inc.
09 June 2010
 

Embargoed: 0700hrs, 9 June 2010

 

 

Akers Biosciences, Inc.

("ABI" or the "Company")

 

ABI Releases BreathScan PRO to Merge Disposable Convenience and Quantitative Precision

 

Akers Biosciences, Inc (AIM:AKR), a leading designer and manufacturer of rapid diagnostic screening and testing products, today announces the initiation of production of a BreathScan alcohol detection product line extension designed for forensic use by trained professionals in law enforcement and other applicable markets, merging the convenience of the Company's proprietary breath alcohol detection technology with the quantitative precision of an electronic analyzer. The System will be branded under the trade name BreathScan PRO and will allow users to determine a subject's breath alcohol level within the range of 0.00% to 0.15%. A test result that is calculated above that range will display on the analyzer's digital read-out as ">0.15%".

The BreathScan PRO system will utilize a specially formulated disposable alcohol detector to collect a breath sample from each test subject. The used detector is then inserted into the BreathScan PRO digital analyzer to obtain a quantitative breath alcohol level for each individual.

Initially, the system will be marketed worldwide for forensic use by trained professionals, including those in civil and military law enforcement, human resources, educational supervision and other safety-related occupations. Some of the scenarios for product use within the "forensic" marketplace will include the following:

·; breath alcohol screenings that seek to quickly and safely establish probable cause for further sobriety or evidential testing by police officers;

·; the assessment of compliance with alcohol safety initiatives related to correctional facilities, work-release programs, employee testing, and school-related events.

User studies are underway to support the Company's application for 510(k) clearance by the US Food and Drug Administration. ABI will seek an Over-the-Counter designation which would further expand the user base of the product in the United States.

ABI will be opening pre-sale of the BreathScan PRO system to its existing distribution network immediately and anticipate that the delivery of the product will commence in September 2010. Product launch to new distributors worldwide will begin early Q4 2010.

Some of the functional highlights of the BreathScan PRO system include the following:

 

·; The one-to-one ratio between breath alcohol detector and breath sample translates into a number of advantages. For one, using the portable BreathScan PRO detectors, several professionals can obtain breath alcohol samples from many test subjects at multiple points of entry/exit. The detectors can then be interpreted by the digital analyzer from within 2 minutes to as long as one hour after the breath sample is obtained. In addition, there is no threat of cross contamination that may exist with other electronic screening devices; those units require numerous persons to provide a breath sample directly into one electronic analyzer.

·; The BreathScan PRO digital analyzer is factory calibrated and never requires recalibration unlike existing screening devices. As a result, organizations that adopt the BreathScan PRO system do not have to factor in system down-time or added expenses related to recalibration activities.

 

·; Unlike most screening devices, BreathScan PRO can be stored and operated at a wide range of temperature conditions(-15C to 50C).

 

Thomas A. Nicolette, President and Chief Executive of ABI, commented,

 

"BreathScan PRO uniquely combines the advantages of one-time use technology with digital sample analysis. The integration of an enduring, electronic reader with custom-calibrated, BreathScan PRO disposable detectors continues our business model focused on recurring revenues. From a competitive standpoint, we are confident that the many advantages of this line extension will be attractive to the global marketplace."

Enquiries:

Thomas A. Nicolette

President and CEO

Tel. +1 856 848 8698

Ben Simons

M: Communications

Tel. +44 (0)20 7920 2340

 

Simon Leathers

Daniel Stewart

Tel. +44 (0)20 7776 6550

 

 

About Akers Biosciences, Inc.

 

Akers Biosciences develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring healthcare information both rapidly and directly to the consumer or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. ABI has aligned with major healthcare companies and high volume medical products distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics. Additional information on the Company and it products can be found at www.akersbiosciences.com

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCZVLFBBQFEBBQ
Date   Source Headline
6th Mar 20197:00 amRNSResult of Special Meeting of Shareholders
6th Feb 20199:00 amRNSHolding in Company
6th Feb 20197:01 amRNSForm DEFA14A Filing - Additional Proxy Materials
6th Feb 20197:00 amRNSNotice of Special Meeting of Shareholders
5th Feb 20191:00 pmRNSFurther Re. Directorate Change
28th Jan 20197:00 amRNSForm PRE 14A Filing
28th Dec 20183:45 pmRNSDirector/PDMR Shareholding
19th Dec 20184:45 pmRNSIntention to Delist from AIM
18th Dec 20186:00 pmRNSIssue of Equity
10th Dec 20187:00 amRNSResult of AGM & Form 8-K Filing
26th Nov 20182:00 pmRNSFurther Re. Notice of AGM
19th Nov 20182:00 pmRNSFurther Re. Strategic Update
16th Nov 20184:00 pmRNSReverse Stock Split Update
15th Nov 20187:00 amRNSNotice of AGM
15th Nov 20187:00 amRNS3rd Quarter 2018 Results
12th Nov 20187:00 amRNSForm 8-K Filing
8th Nov 20187:30 amRNSSuspension - Akers Biosciences, Inc.
8th Nov 20187:00 amRNSTemporary Suspension of Share Trading on LSE
7th Nov 20182:50 pmRNSStrategic Update & Reverse Stock Split
2nd Nov 20184:15 pmRNSIssue of Equity - Completion & Form 8-K/A Filing
2nd Nov 201810:52 amRNSUpdate Re Issue of Equity
31st Oct 20181:35 pmRNSIssue of Equity & Form 8-K
19th Oct 20182:53 pmRNSForm 8-K Filing
19th Oct 20187:00 amRNSDirectorate Change
12th Oct 20187:00 amRNSForm 8-K/A Filing & Other Updates
8th Oct 20187:00 amRNSDirectorate Change & Other Information
13th Sep 20187:00 amRNSDirectorate Change - Form 8-K Filing
15th Aug 20187:00 amRNS2nd Quarter & H1 2018 Results
27th Jul 20183:00 pmRNSHolding(s) in Company
26th Jul 20187:30 amRNSRestoration - Akers Biosciences Inc.
26th Jul 20187:00 amRNSMailing of 2017 Annual Report
20th Jul 20183:05 pmRNSIssue of Equity
20th Jul 20183:00 pmRNSCorrection: Issue of Equity
18th Jul 201812:00 pmRNSIndependent Sales Representative Agreements - PIFA
16th Jul 20187:03 amRNS1st Quarter 2018 Results
16th Jul 20187:02 amRNSFinal Results 2017 (Restated)
16th Jul 20187:01 amRNS3rd Quarter 2017 Results (Restated)
16th Jul 20187:00 amRNS2nd Quarter 2017 Results (Restated)
3rd Jul 201812:00 pmRNSIndependent Sales Representative Agreements - PIFA
2nd Jul 20187:30 amRNSSuspension - Akers Bioscience, Inc
29th Jun 20187:00 amRNSTemporary Suspension
21st Jun 20187:00 amRNSNotification of Class Action
20th Jun 20187:22 amRNSForm 8-K Filing
18th Jun 20187:00 amRNSForm 8-K Filing
6th Jun 20187:00 amRNSForm 8-K/A Filing
4th Jun 20187:00 amRNSForm 8-K Filing
31st May 20187:25 amRNSUpdate Re. Nasdaq Minimum Bid Price Requirement
29th May 20187:00 amRNSDirectorate Change
29th May 20187:00 amRNSWithdrawal of 510(k) Submission - Chlamydia Assay
29th May 20187:00 amRNSNotice of Form 10-Q Filing Delinquency from Nasdaq

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.